Display options
Cite
Keller KE, Peters DM. Pathogenesis of glaucoma: Extracellular matrix dysfunction in the trabecular meshwork-A review. Clin Exp Ophthalmol. 2022;doi: 10.1111/ceo.14027.
Keller, K. E., & Peters, D. M. (2022). Pathogenesis of glaucoma: Extracellular matrix dysfunction in the trabecular meshwork-A review. Clinical & experimental ophthalmology, . https://doi.org/10.1111/ceo.14027
Keller, Kate E, and Peters, Donna M. "Pathogenesis of glaucoma: Extracellular matrix dysfunction in the trabecular meshwork-A review." Clinical & experimental ophthalmology vol. (2022). doi: https://doi.org/10.1111/ceo.14027
Keller KE, Peters DM. Pathogenesis of glaucoma: Extracellular matrix dysfunction in the trabecular meshwork-A review. Clin Exp Ophthalmol. 2022 Jan 17; doi: 10.1111/ceo.14027. Epub 2022 Jan 17. PMID: 35037377.
Copy Download .nbib Format: NLM
Share it on

Clin Exp Ophthalmol. 2022 Jan 17; doi: 10.1111/ceo.14027. Epub 2022 Jan 17.

Pathogenesis of glaucoma: Extracellular matrix dysfunction in the trabecular meshwork-A review.

Clinical & experimental ophthalmology

Kate E Keller, Donna M Peters

Affiliations

  1. Casey Eye Institute, Oregon Health &Science University, Portland, Oregon, USA.
  2. Department of Pathology & Laboratory Medicine, University of Wisconsin School of Medicine & Public Health, Madison, Wisconsin, USA.

PMID: 35037377 DOI: 10.1111/ceo.14027

Abstract

The trabecular meshwork regulates aqueous humour outflow from the anterior chamber of the eye. It does this by establishing a tunable outflow resistance, defined by the interplay between cells and their extracellular matrix (ECM) milieu, and the molecular interactions between ECM proteins. During normal tissue homeostasis, the ECM is remodelled and trabecular cell behaviour is modified, permitting increased aqueous fluid outflow to maintain intraocular pressure (IOP) within a relatively narrow physiological pressure. Dysfunction in the normal homeostatic process leads to increased outflow resistance and elevated IOP, which is a primary risk factor for glaucoma. This review delineates some of the changes in the ECM that lead to gross as well as some more subtle changes in the structure and function of the ECM, and their impact on trabecular cell behaviour. These changes are discussed in the context of outflow resistance and glaucoma.

© 2021 Royal Australian and New Zealand College of Ophthalmologists.

Keywords: extracellular matrix; glaucoma; trabecular meshwork

References

  1. Stamer WD, Acott TS. Current understanding of conventional outflow dysfunction in glaucoma. Curr Opin Ophthalmol. 2012;23:135-143. - PubMed
  2. Acott TS, Vranka JA, Keller KE, Raghunathan V, Kelley MJ. Normal and glaucomatous outflow regulation. Prog Retin Eye Res. 2021;82:100897. - PubMed
  3. Johnson M. What controls aqueous humour outflow resistance? Exp Eye Res. 2006;82:545-557. - PubMed
  4. Braunger BM, Fuchshofer R, Tamm ER. The aqueous humor outflow pathways in glaucoma: a unifying concept of disease mechanisms and causative treatment. Eur J Pharm Biopharm. 2015;95:173-181. - PubMed
  5. Roy Chowdhury U, Hann CR, Stamer WD, Fautsch MP. Aqueous humor outflow: dynamics and disease. Invest Ophthalmol Vis Sci. 2015;56:2993-3003. - PubMed
  6. Acott TS, Kelley MJ. Extracellular matrix in the trabecular meshwork. Exp Eye Res. 2008;86:543-561. - PubMed
  7. Sacca SC, Gandolfi S, Bagnis A, et al. The outflow pathway: a tissue with morphological and functional unity. J Cell Physiol. 2016;231:1876-1893. - PubMed
  8. Nilsson SF. The uveoscleral outflow routes. Eye (Lond). 1997;11(Pt 2):149-154. - PubMed
  9. Pederson JE, Toris CB. Uveoscleral outflow: diffusion or flow? Invest Ophthalmol Vis Sci. 1987;28:1022-1024. - PubMed
  10. Goel M, Picciani RG, Lee RK, Bhattacharya SK. Aqueous humor dynamics: a review. Open Ophthalmol J. 2010;4:52-59. - PubMed
  11. Lin CW, Sherman B, Moore LA, et al. Discovery and preclinical development of netarsudil, a novel ocular hypotensive agent for the treatment of glaucoma. J Ocul Pharmacol Ther. 2018;34:40-51. - PubMed
  12. Johnson M, McLaren JW, Overby DR. Unconventional aqueous humor outflow: a review. Exp Eye Res. 2017;158:94-111. - PubMed
  13. Tamm ER. The trabecular meshwork outflow pathways: structural and functional aspects. Exp Eye Res. 2009;88:648-655. - PubMed
  14. Rohen JW, van der Zypen E. The phagocytic activity of the trabecular meshwork endothelium. An electron-microscopic study of the vervet (Cercopithecus aethiops). Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1968;175:143-160. - PubMed
  15. Rohen JW, Lutjen-Drecoll E. Biology of the trabecular meshwork. In: Lutjen-Drecoll E, ed. Biology of the Trabecular Meshwork. Stuttgart, New York; 1982. - PubMed
  16. Rohen JW, Futa R, Lutjen-Drecoll E. The fine structure of the cribriform meshwork in normal and glaucomatous eyes as seen in tangential sections. Invest Ophthalmol Vis Sci. 1981;21:574-585. - PubMed
  17. Keller KE, Acott TS. The juxtacanalicular region of ocular trabecular meshwork: a tissue with a unique extracellular matrix and specialized function. J Ocular Biol. 2013;1:10. - PubMed
  18. Gong H, Tripathi RC, Tripathi BJ. Morphology of the aqueous outflow pathway. Microsc Res Tech. 1996;33:336-367. - PubMed
  19. Lutjen-Drecoll E. Functional morphology of the trabecular meshwork in primate eyes. Prog Retin Eye Res. 1999;18:91-119. - PubMed
  20. Fuchshofer R, Welge-Lussen U, Lutjen-Drecoll E, Birke M. Biochemical and morphological analysis of basement membrane component expression in corneoscleral and cribriform human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2006;47:794-801. - PubMed
  21. Maepea O, Bill A. The pressures in the episcleral veins, Schlemm's canal and the trabecular meshwork in monkeys: effects of changes in intraocular pressure. Exp Eye Res. 1989;49:645-663. - PubMed
  22. Carreon T, van der Merwe E, Fellman RL, Johnstone M, Bhattacharya SK. Aqueous outflow - a continuum from trabecular meshwork to episcleral veins. Prog Retin Eye Res. 2017;57:108-133. - PubMed
  23. Vranka JA, Bradley JM, Yang YF, Keller KE, Acott TS. Mapping molecular differences and extracellular matrix gene expression in segmental outflow pathways of the human ocular trabecular meshwork. PLoS One. 2015;10:e0122483. - PubMed
  24. Buller C, Johnson D. Segmental variability of the trabecular meshwork in normal and glaucomatous eyes. Invest Ophthalmol Vis Sci. 1994;35:3841-3851. - PubMed
  25. Ethier CR, Chan DW. Cationic ferritin changes outflow facility in human eyes whereas anionic ferritin does not. Invest Ophthalmol Vis Sci. 2001;42:1795-1802. - PubMed
  26. Hann CR, Bahler CK, Johnson DH. Cationic ferritin and segmental flow through the trabecular meshwork. Invest Ophthalmol Vis Sci. 2005;46:1-7. - PubMed
  27. Battista SA, Lu Z, Hofmann S, Freddo T, Overby DR, Gong H. Reduction of the available area for aqueous humor outflow and increase in meshwork herniations into collector channels following acute IOP elevation in bovine eyes. Invest Ophthalmol Vis Sci. 2008;49:5346-5352. - PubMed
  28. Lu Z, Overby DR, Scott PA, Freddo TF, Gong H. The mechanism of increasing outflow facility by rho-kinase inhibition with Y-27632 in bovine eyes. Exp Eye Res. 2008;86:271-281. - PubMed
  29. Melamed S, Freddo TF, Epstein DL. Use of cationized ferritin to trace aqueous humor outflow in the monkey eye. Exp Eye Res. 1986;43:273-278. - PubMed
  30. Keller KE, Bradley JM, Vranka JA, Acott TS. Segmental versican expression in the trabecular meshwork and involvement in outflow facility. Invest Ophthalmol Vis Sci. 2011;52:5049-5057. - PubMed
  31. Hann CR, Fautsch MP. Preferential fluid flow in the human trabecular meshwork near collector channels. Invest Ophthalmol Vis Sci. 2009;50:1692-1697. - PubMed
  32. Parc CE, Johnson DH, Brilakis HS. Giant vacuoles are found preferentially near collector channels. Invest Ophthalmol Vis Sci. 2000;41:2984-2990. - PubMed
  33. Quigley HA. Glaucoma. Lancet. 2011;377:1367-1377. - PubMed
  34. Ueda J, Wentz-Hunter K, Yue BY. Distribution of myocilin and extracellular matrix components in the juxtacanalicular tissue of human eyes. Invest Ophthalmol Vis Sci. 2002;43:1068-1076. - PubMed
  35. Alvarado J, Murphy C, Juster R. Trabecular meshwork cellularity in primary open-angle glaucoma and nonglaucomatous normals. Ophthalmology. 1984;91:564-579. - PubMed
  36. Tripathi RC, Li J, Chan WF, Tripathi BJ. Aqueous humor in glaucomatous eyes contains an increased level of TGF-beta 2. Exp Eye Res. 1994;59:723-727. - PubMed
  37. Picht G, Welge-Luessen U, Grehn F, Lutjen-Drecoll E. Transforming growth factor beta 2 levels in the aqueous humor in different types of glaucoma and the relation to filtering bleb development. Graefes Arch Clin Exp Ophthalmol. 2001;239:199-207. - PubMed
  38. Roberts AB, McCune BK, Sporn MB. TGF-beta: regulation of extracellular matrix. Kidney Int. 1992;41:557-559. - PubMed
  39. Tominaga K, Suzuki HI. TGF-beta signaling in cellular senescence and aging-related pathology. Int J Mol Sci. 2019;20:5002. - PubMed
  40. Rapisarda V, Borghesan M, Miguela V, et al. Integrin Beta 3 regulates cellular senescence by activating the TGF-beta pathway. Cell Rep. 2017;18:2480-2493. - PubMed
  41. Becker B. Intraocular pressure response to topical corticosteroids. Investig Ophthalmol. 1965;4:198-205. - PubMed
  42. Tektas OY, Lutjen-Drecoll E. Structural changes of the trabecular meshwork in different kinds of glaucoma. Exp Eye Res. 2009;88:769-775. - PubMed
  43. Tawara A, Tou N, Kubota T, Harada Y, Yokota K. Immunohistochemical evaluation of the extracellular matrix in trabecular meshwork in steroid-induced glaucoma. Graefes Arch Clin Exp Ophthalmol. 2008;246:1021-1028. - PubMed
  44. Zhang X, Ognibene CM, Clark AF, Yorio T. Dexamethasone inhibition of trabecular meshwork cell phagocytosis and its modulation by glucocorticoid receptor beta. Exp Eye Res. 2007;84:275-284. - PubMed
  45. Bermudez JY, Montecchi-Palmer M, Mao W, Clark AF. Cross-linked Actin networks (CLANs) in glaucoma. Exp Eye Res. 2017;159:16-22. - PubMed
  46. Filla MS, Schwinn MK, Nosie AK, Clark RW, Peters DM. Dexamethasone-associated cross-linked Actin network formation in human trabecular meshwork cells involves beta3 integrin signaling. Invest Ophthalmol Vis Sci. 2011;52:2952-2959. - PubMed
  47. Peters DM, Herbert K, Biddick B, Peterson JA. Myocilin binding to Hep II domain of fibronectin inhibits cell spreading and incorporation of paxillin into focal adhesions. Exp Cell Res. 2005;303:218-228. - PubMed
  48. Kwon HS, Tomarev SI. Myocilin, a glaucoma-associated protein, promotes cell migration through activation of integrin-focal adhesion kinase-serine/threonine kinase signaling pathway. J Cell Physiol. 2011;226:3392-3402. - PubMed
  49. Wentz-Hunter K, Shen X, Okazaki K, Tanihara H, Yue BY. Overexpression of myocilin in cultured human trabecular meshwork cells. Exp Cell Res. 2004;297:39-48. - PubMed
  50. Faralli JA, Gagen D, Filla MS, Crotti TN, Peters DM. Dexamethasone increases αvβ3 integrin expression and affinity through a calcineurin/NFAT pathway. Biochim Biophys Acta. 2013;1833:3306-3313. - PubMed
  51. Gagen D, Filla MS, Clark R, Liton P, Peters DM. Activated αvβ3 integrin regulates αvβ5 integrin-mediated phagocytosis in trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2013;54:5000-5011. - PubMed
  52. Faralli JA, Filla MS, Peters DM. Effect of αvβ3 integrin expression and activity on intraocular pressure. Invest Ophthalmol Vis Sci. 2019;60:1776-1788. - PubMed
  53. Schlotzer-Schrehardt U. Molecular pathology of pseudoexfoliation syndrome/glaucoma- -new insights from LOXL1 gene associations. Exp Eye Res. 2009;88:776-785. - PubMed
  54. Schlotzer-Schrehardt U, Pasutto F, Sommer P, et al. Genotype-correlated expression of lysyl oxidase-like 1 in ocular tissues of patients with pseudoexfoliation syndrome/glaucoma and normal patients. Am J Pathol. 2008;173:1724-1735. - PubMed
  55. Schlotzer-Schrehardt U, Khor CC. Pseudoexfoliation syndrome and glaucoma: from genes to disease mechanisms. Curr Opin Ophthalmol. 2021;32:118-128. - PubMed
  56. Browne JG, Ho SL, Kane R, et al. Connective tissue growth factor is increased in pseudoexfoliation glaucoma. Invest Ophthalmol Vis Sci. 2011;52:3660-3666. - PubMed
  57. Elahi E. Genetic basis of primary angle closure glaucoma: the role of collagens and extracellular matrix. J Ophthalmic Vis Res. 2020;15:1-3. - PubMed
  58. Suri F, Yazdani S, Chapi M, et al. COL18A1 is a candidate eye iridocorneal angle-closure gene in humans. Hum Mol Genet. 2018;27:3772-3786. - PubMed
  59. Vithana EN, Khor CC, Qiao C, et al. Genome-wide association analyses identify three new susceptibility loci for primary angle closure glaucoma. Nat Genet. 2012;44:1142-1146. - PubMed
  60. Chow WY, Forman CJ, Bihan D, et al. Proline provides site-specific flexibility for in vivo collagen. Sci Rep. 2018;8:13809. - PubMed
  61. Lewis CJ, Hedberg-Buenz A, DeLuca AP, Stone EM, Alward WLM, Fingert JH. Primary congenital and developmental glaucomas. Hum Mol Genet. 2017;26:R28-R36. - PubMed
  62. Ali M, McKibbin M, Booth A, et al. Null mutations in LTBP2 cause primary congenital glaucoma. Am J Hum Genet. 2009;84:664-671. - PubMed
  63. Kuehn MH, Lipsett KA, Menotti-Raymond M, et al. A mutation in LTBP2 causes congenital glaucoma in domestic cats (Felis catus). PLoS One. 2016;11:e0154412. - PubMed
  64. Kadler KE, Baldock C, Bella J, Boot-Handford RP. Collagens at a glance. J Cell Sci. 2007;120:1955-1958. - PubMed
  65. Ricard-Blum S. The collagen family. Cold Spring Harb Perspect Biol. 2011;3:a004978. - PubMed
  66. Liu X, Wu H, Byrne M, Jeffrey J, Krane S, Jaenisch R. A targeted mutation at the known collagenase cleavage site in mouse type I collagen impairs tissue remodeling. J Cell Biol. 1995;130:227-237. - PubMed
  67. Aihara M, Lindsey JD, Weinreb RN. Ocular hypertension in mice with a targeted type I collagen mutation. Invest Ophthalmol Vis Sci. 2003;44:1581-1585. - PubMed
  68. Birk DE, Fitch JM, Babiarz JP, Doane KJ, Linsenmayer TF. Collagen fibrillogenesis in vitro: interaction of types I and V collagen regulates fibril diameter. J Cell Sci. 1990;95:649-657. - PubMed
  69. Vithana EN, Aung T, Khor CC, et al. Collagen-related genes influence the glaucoma risk factor, central corneal thickness. Hum Mol Genet. 2011;20:649-658. - PubMed
  70. Mak KM, Mei R. Basement membrane type IV collagen and laminin: an overview of their biology and value as fibrosis biomarkers of liver disease. Anat Rec. 2017;300:1371-1390. - PubMed
  71. Hann CR, Springett MJ, Wang X, Johnson DH. Ultrastructural localization of collagen IV, fibronectin, and laminin in the trabecular meshwork of normal and glaucomatous eyes. Ophthalmic Res. 2001;33:314-324. - PubMed
  72. Lutjen-Drecoll E, Rittig M, Rauterberg J, Jander R, Mollenhauer J. Immunomicroscopical study of type VI collagen in the trabecular meshwork of normal and glaucomatous eyes. Exp Eye Res. 1989;48:139-147. - PubMed
  73. LeBleu VS, Macdonald B, Kalluri R. Structure and function of basement membranes. Exp Biol Med (Maywood). 2007;232:1121-1129. - PubMed
  74. Brassart-Pasco S, Senechal K, Thevenard J, et al. Tetrastatin, the NC1 domain of the α4(IV) collagen chain: a novel potent anti-tumor matrikine. PLoS One. 2012;7:e29587. - PubMed
  75. Sudhakar YA, Verma RK, Pawar SC. Type IV collagen alpha1-chain noncollagenous domain blocks MMP-2 activation both in-vitro and in-vivo. Sci Rep. 2014;4:4136. - PubMed
  76. Cescon M, Gattazzo F, Chen P, Bonaldo P. Collagen VI at a glance. J Cell Sci. 2015;128:3525-3531. - PubMed
  77. Lamande SR, Sigalas E, Pan TC, et al. The role of the α3(VI) chain in collagen VI assembly. Expression of an α3(VI) chain lacking N-terminal modules N10-N7 restores collagen VI assembly, secretion, and matrix deposition in an α3(VI)-deficient cell line. J Biol Chem. 1998;273:7423-7430. - PubMed
  78. Lutjen-Drecoll E, Shimizu T, Rohrbach M, Rohen JW. Quantitative analysis of 'plaque material' in the inner- and outer wall of Schlemm's canal in normal- and glaucomatous eyes. Exp Eye Res. 1986;42:443-455. - PubMed
  79. Vranka JA, Staverosky JA, Reddy AP, et al. Biomechanical rigidity and quantitative proteomics analysis of segmental regions of the trabecular meshwork at physiologic and elevated pressures. Invest Ophthalmol Vis Sci. 2018;59:246-259. - PubMed
  80. Choquet H, Thai KK, Yin J, et al. A large multi-ethnic genome-wide association study identifies novel genetic loci for intraocular pressure. Nat Commun. 2017;8:2108. - PubMed
  81. Wirtz MK, Sykes RL, Samples JR, et al. Identification of missense extracellular matrix gene variants in a large glaucoma pedigree and investigation of the N700S thrombospondin-1 variant in normal and glaucomatous trabecular meshwork cells. Curr Eye Res. 2021;6:1-12. - PubMed
  82. Faralli JA, Filla MS, Peters DM. Role of fibronectin in primary open angle glaucoma. Cells. 2019;8:1518. - PubMed
  83. Fuchshofer R, Tamm ER. The role of TGF-beta in the pathogenesis of primary open-angle glaucoma. Cell Tissue Res. 2012;347:279-290. - PubMed
  84. Reid T, Kenney C, Waring GO. Isolation and characterization of fibronectin from bovine aqueous humor. Invest Ophthalmol Vis Sci. 1982;22:57-61. - PubMed
  85. Hynes RO. Fibronectins. Springer-Verlag; 1990. - PubMed
  86. Singh P, Carraher C, Schwarzbauer JE. Assembly of fibronectin extracellular matrix. Annu Rev Cell Dev Biol. 2010;26:397-419. - PubMed
  87. Babizhayev MA, Brodskaya MW. Fibronectin detection in drainage outflow system of human eyes in ageing and progression of open-angle glaucoma. Mech Ageing Dev. 1989;47:145-157. - PubMed
  88. Filla MS, Dimeo KD, Tong T, Peters DM. Disruption of fibronectin matrix affects type IV collagen, fibrillin and laminin deposition into extracellular matrix of human trabecular meshwork (HTM) cells. Exp Eye Res. 2017;165:7-19. - PubMed
  89. Zhu J, Clark RAF. Fibronectin at select sites binds multiple growth factors and enhances their activity: expansion of the collaborative ECM-GF paradigm. J Invest Dermatol. 2014;134:895-901. - PubMed
  90. Santas AJ, Bahler C, Peterson JA, et al. Effect of heparin II domain of fibronectin on aqueous outflow in cultured anterior segments of human eyes. Invest Ophthalmol Vis Sci. 2003;44:4796-4804. - PubMed
  91. Gonzalez JM Jr, Hu Y, Gabelt BT, Kaufman PL, Peters DM. Identification of the active site in the heparin II domain of fibronectin that increases outflow facility in cultured monkey anterior segments. Invest Ophthalmol Vis Sci. 2009;50:235-241. - PubMed
  92. Yasuda T, Shimizu M, Nakagawa T, Julovi SM, Nakamura T. Matrix metalloproteinase production by COOH-terminal heparin-binding fibronectin fragment in rheumatoid synovial cells. Lab Investig. 2003;83:153-162. - PubMed
  93. Xie DL, Meyers R, Homandberg GA. Fibronectin fragments in osteoarthritic synovial fluid. J Rheumatol. 1992;19:1448-1452. - PubMed
  94. Hamanaka T, Kimura M, Sakurai T, et al. A histologic categorization of aqueous outflow routes in familial open-angle glaucoma and associations with mutations in the MYOC gene in Japanese patients. Invest Ophthalmol Vis Sci. 2017;58:2818-2831. - PubMed
  95. Reina-Torres E, Wen JC, Liu KC, et al. VEGF as a paracrine regulator of conventional outflow facility. Invest Ophthalmol Vis Sci. 2017;58:1899-1908. - PubMed
  96. Wijelath ES, Rahman S, Namekata M, et al. Heparin-II domain of fibronectin is a vascular endothelial growth factor-binding domain: enhancement of VEGF biological activity by a singular growth factor/matrix protein synergism. Circ Res. 2006;99:853-860. - PubMed
  97. Hu DN, Ritch R, Liebmann J, Liu Y, Cheng B, Hu MS. Vascular endothelial growth factor is increased in aqueous humor of glaucomatous eyes. J Glaucoma. 2002;11:406-410. - PubMed
  98. Gavard J, Gutkind JS. VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. Nat Cell Biol. 2006;8:1223-1234. - PubMed
  99. Fujimoto T, Inoue T, Maki K, Inoue-Mochita M, Tanihara H. Vascular endothelial growth factor-a increases the aqueous humor outflow facility. PLoS One. 2016;11:e0161332. - PubMed
  100. Faralli JA, Schwinn MK, Gonzalez JM Jr, Filla MS, Peters DM. Functional properties of fibronectin in the trabecular meshwork. Exp Eye Res. 2009;88:689-693. - PubMed
  101. Vittal V, Rose A, Gregory KE, Kelley MJ, Acott TS. Changes in gene expression by trabecular meshwork cells in response to mechanical stretching. Invest Ophthalmol Vis Sci. 2005;46:2857-2868. - PubMed
  102. Medina-Ortiz WE, Belmares R, Neubauer S, Wordinger RJ, Clark AF. Cellular fibronectin expression in human trabecular meshwork and induction by transforming growth factor-beta2. Invest Ophthalmol Vis Sci. 2013;54:6779-6788. - PubMed
  103. Keller KE, Kelley MJ, Acott TS. Extracellular matrix gene alternative splicing by trabecular meshwork cells in response to mechanical stretching. Invest Ophthalmol Vis Sci. 2007;48:1164-1172. - PubMed
  104. Ventura E, Weller M, Macnair W, et al. TGF-beta induces oncofetal fibronectin that, in turn, modulates TGF-beta superfamily signaling in endothelial cells. J Cell Sci. 2018;131:jcs209619. - PubMed
  105. Schiefner A, Gebauer M, Skerra A. Extra-domain B in oncofetal fibronectin structurally promotes fibrillar head-to-tail dimerization of extracellular matrix protein. J Biol Chem. 2012;287:17578-17588. - PubMed
  106. Bhattacharyya S, Tamaki Z, Wang W, et al. Fibronectin EDA promotes chronic cutaneous fibrosis through toll-like receptor signaling. Sci Transl Med. 2014;6:232ra50. - PubMed
  107. Roberts AL, Mavlyutov TA, Perlmutter TE, et al. Fibronectin extra domain A (FN-EDA) elevates intraocular pressure through toll-like receptor 4 signaling. Sci Rep. 2020;10:9815. - PubMed
  108. Trusolino L, Serini G, Cecchini G, et al. Growth factor-dependent activation of alphavbeta3 integrin in normal epithelial cells: implications for tumor invasion. J Cell Biol. 1998;142:1145-1156. - PubMed
  109. Bencharit S, Cui CB, Siddiqui A, et al. Structural insights into fibronectin type III domain-mediated signaling. J Mol Biol. 2007;367:303-309. - PubMed
  110. Chen S, Chakrabarti R, Keats EC, Chen M, Chakrabarti S, Khan ZA. Regulation of vascular endothelial growth factor expression by extra domain B segment of fibronectin in endothelial cells. Invest Ophthalmol Vis Sci. 2012;53:8333-8343. - PubMed
  111. Kraft S, Klemis V, Sens C, et al. Identification and characterization of a unique role for EDB fibronectin in phagocytosis. J Mol Med. 2016;94:567-581. - PubMed
  112. Efthymiou G, Radwanska A, Grapa AI, et al. Fibronectin extra domains tune cellular responses and confer topographically distinct features to fibril networks. J Cell Sci. 2021;134:jcs252957. - PubMed
  113. Manabe R, Ohe N, Maeda T, Fukuda T, Sekiguchi K. Modulation of cell-adhesive activity of fibronectin by the alternatively spliced EDA segment. J Cell Biol. 1997;139:295-307. - PubMed
  114. Aumailley M. The laminin family. Cell Adhes Migr. 2013;7:48-55. - PubMed
  115. Aumailley M, Bruckner-Tuderman L, Carter WG, et al. A simplified laminin nomenclature. Matrix Biol. 2005;24:326-332. - PubMed
  116. Dietlein TS, Jacobi PC, Paulsson M, Smyth N, Krieglstein GK. Laminin heterogeneity around Schlemm's canal in normal humans and glaucoma patients. Ophthalmic Res. 1998;30:380-387. - PubMed
  117. Dickerson JE Jr, Steely HT Jr, English-Wright SL, Clark AF. The effect of dexamethasone on integrin and laminin expression in cultured human trabecular meshwork cells. Exp Eye Res. 1998;66:731-738. - PubMed
  118. Bredrup C, Matejas V, Barrow M, et al. Ophthalmological aspects of Pierson syndrome. Am J Ophthalmol. 2008;146:602-611. - PubMed
  119. Baldwin AK, Simpson A, Steer R, Cain SA, Kielty CM. Elastic fibres in health and disease. Expert Rev Mol Med. 2013;15:e8. - PubMed
  120. Kuchtey J, Kuchtey RW. The microfibril hypothesis of glaucoma: implications for treatment of elevated intraocular pressure. J Ocul Pharmacol Ther. 2014;30:170-180. - PubMed
  121. Kielty CM, Sherratt MJ, Shuttleworth CA. Elastic fibres. J Cell Sci. 2002;115:2817-2828. - PubMed
  122. Hann CR, Fautsch MP. The elastin fiber system between and adjacent to collector channels in the human juxtacanalicular tissue. Invest Ophthalmol Vis Sci. 2011;52:45-50. - PubMed
  123. Robertson IB, Horiguchi M, Zilberberg L, Dabovic B, Hadjiolova K, Rifkin DB. Latent TGF-beta-binding proteins. Matrix Biol. 2015;47:44-53. - PubMed
  124. Knepper PA, Goossens W, Hvizd M, Palmberg PF. Glycosaminoglycans of the human trabecular meshwork in primary open-angle glaucoma. Invest Ophthalmol Vis Sci. 1996;37:1360-1367. - PubMed
  125. Crawford SE, Stellmach V, Murphy-Ullrich JE, et al. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell. 1998;93:1159-1170. - PubMed
  126. Worthington JJ, Klementowicz JE, Travis MA. TGFbeta: a sleeping giant awoken by integrins. Trends Biochem Sci. 2011;36:47-54. - PubMed
  127. Dietz HC, Cutting GR, Pyeritz RE, et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature. 1991;352:337-339. - PubMed
  128. Reinhardt DP. Microfibril-associated disorders: fibrillinopathies. J Glaucoma. 2014;23:S34-S35. - PubMed
  129. Bornstein P, Sage EH. Matricellular proteins: extracellular modulators of cell function. Curr Opin Cell Biol. 2002;14:608-616. - PubMed
  130. Murphy-Ullrich JE, Sage EH. Revisiting the matricellular concept. Matrix Biol. 2014;37:1-14. - PubMed
  131. Adams JC, Lawler J. The thrombospondins. Cold Spring Harb Perspect Biol. 2011;3:a009712. - PubMed
  132. Murphy-Ullrich JE, Downs JC. The Thrombospondin1-TGF-beta pathway and glaucoma. J Ocul Pharmacol Ther. 2015;31:371-375. - PubMed
  133. Flugel-Koch C, Ohlmann A, Fuchshofer R, Welge-Lussen U, Tamm ER. Thrombospondin-1 in the trabecular meshwork: localization in normal and glaucomatous eyes, and induction by TGF-beta1 and dexamethasone in vitro. Exp Eye Res. 2004;79:649-663. - PubMed
  134. Bornstein P. Thrombospondins: structure and regulation of expression. FASEB J. 1992;6:3290-3299. - PubMed
  135. Resovi A, Pinessi D, Chiorino G, Taraboletti G. Current understanding of the thrombospondin-1 interactome. Matrix Biol. 2014;37:83-91. - PubMed
  136. Haddadin RI, Oh DJ, Kang MH, et al. Thrombospondin-1 (TSP1)-null and TSP2-null mice exhibit lower intraocular pressures. Invest Ophthalmol Vis Sci. 2012;53:6708-6717. - PubMed
  137. Topol EJ, McCarthy J, Gabriel S, et al. Single nucleotide polymorphisms in multiple novel thrombospondin genes may be associated with familial premature myocardial infarction. Circulation. 2001;104:2641-2644. - PubMed
  138. Zwicker JI, Peyvandi F, Palla R, et al. The thrombospondin-1 N700S polymorphism is associated with early myocardial infarction without altering von Willebrand factor multimer size. Blood. 2006;108:1280-1283. - PubMed
  139. Kvansakul M, Adams JC, Hohenester E. Structure of a thrombospondin C-terminal fragment reveals a novel calcium core in the type 3 repeats. EMBO J. 2004;23:1223-1233. - PubMed
  140. Hannah BL, Misenheimer TM, Pranghofer MM, Mosher DF. A polymorphism in thrombospondin-1 associated with familial premature coronary artery disease alters Ca2+ binding. J Biol Chem. 2004;279:51915-51922. - PubMed
  141. Narizhneva NV, Byers-Ward VJ, Quinn MJ, et al. Molecular and functional differences induced in thrombospondin-1 by the single nucleotide polymorphism associated with the risk of premature, familial myocardial infarction. J Biol Chem. 2004;279:21651-21657. - PubMed
  142. Carlson CB, Gunderson KA, Mosher DF. Mutations targeting intermodular interfaces or calcium binding destabilize the thrombospondin-2 signature domain. J Biol Chem. 2008;283:27089-27099. - PubMed
  143. Carlson CB, Liu Y, Keck JL, Mosher DF. Influences of the N700S thrombospondin-1 polymorphism on protein structure and stability. J Biol Chem. 2008;283:20069-20076. - PubMed
  144. Midwood KS, Hussenet T, Langlois B, Orend G. Advances in tenascin-C biology. Cell Mol Life Sci. 2011;68:3175-3199. - PubMed
  145. Midwood KS, Chiquet M, Tucker RP, Orend G. Tenascin-C at a glance. J Cell Sci. 2016;129:4321-4327. - PubMed
  146. Mercado ML, Nur-e-Kamal A, Liu HY, Gross SR, Movahed R, Meiners S. Neurite outgrowth by the alternatively spliced region of human tenascin-C is mediated by neuronal α7β1 integrin. J Neurosci. 2004;24:238-247. - PubMed
  147. Rigato F, Garwood J, Calco V, Heck N, Faivre-Sarrailh C, Faissner A. Tenascin-C promotes neurite outgrowth of embryonic hippocampal neurons through the alternatively spliced fibronectin type III BD domains via activation of the cell adhesion molecule F3/contactin. J Neurosci. 2002;22:6596-6609. - PubMed
  148. Keller KE, Vranka JA, Haddadin RI, et al. The effects of tenascin C knockdown on trabecular meshwork outflow resistance. Invest Ophthalmol Vis Sci. 2013;54:5613-5623. - PubMed
  149. Wiemann S, Reinhard J, Reinehr S, Cibir Z, Joachim SC, Faissner A. Loss of the extracellular matrix molecule tenascin-C leads to absence of reactive gliosis and promotes anti-inflammatory cytokine expression in an autoimmune glaucoma mouse model. Front Immunol. 2020;11:566279. - PubMed
  150. Wirtz MK, Bradley JM, Xu H, et al. Proteoglycan expression by human trabecular meshworks. Curr Eye Res. 1997;16:412-421. - PubMed
  151. Rhee DJ, Fariss RN, Brekken R, Sage EH, Russell P. The matricellular protein SPARC is expressed in human trabecular meshwork. Exp Eye Res. 2003;77:601-607. - PubMed
  152. Haddadin RI, Oh DJ, Kang MH, et al. SPARC-null mice exhibit lower intraocular pressures. Invest Ophthalmol Vis Sci. 2009;50:3771-3777. - PubMed
  153. Yu L, Zheng Y, Liu BJ, Kang MH, Millar JC, Rhee DJ. Secreted protein acidic and rich in cysteine (SPARC) knockout mice have greater outflow facility. PLoS One. 2020;15:e0241294. - PubMed
  154. Swaminathan SS, Oh DJ, Kang MH, et al. Secreted protein acidic and rich in cysteine (SPARC)-null mice exhibit more uniform outflow. Invest Ophthalmol Vis Sci. 2013;54:2035-2047. - PubMed
  155. Aroca-Aguilar JD, Sanchez-Sanchez F, Ghosh S, Fernandez-Navarro A, Coca-Prados M, Escribano J. Interaction of recombinant myocilin with the matricellular protein SPARC: functional implications. Invest Ophthalmol Vis Sci. 2011;52:179-189. - PubMed
  156. Luna C, Li G, Liton PB, Epstein DL, Gonzalez P. Alterations in gene expression induced by cyclic mechanical stress in trabecular meshwork cells. Mol Vis. 2009;15:534-544. - PubMed
  157. Kang MH, Oh DJ, Kang JH, Rhee DJ. Regulation of SPARC by transforming growth factor beta2 in human trabecular meshwork. Invest Ophthalmol Vis Sci. 2013;54:2523-2532. - PubMed
  158. Yu AL, Birke K, Moriniere J, Welge-Lussen U. TGF-β2 induces senescence-associated changes in human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2010;51:5718-5723. - PubMed
  159. Gong H, Freddo TF, Johnson M. Age-related changes of sulfated proteoglycans in the normal human trabecular meshwork. Exp Eye Res. 1992;55:691-709. - PubMed
  160. Filla MS, David G, Weinreb RN, Kaufman PL, Peters DM. Distribution of syndecans 1-4 within the anterior segment of the human eye: expression of a variant syndecan-3 and matrix-associated syndecan-2. Exp Eye Res. 2004;79:61-74. - PubMed
  161. Schneider M, Pawlak R, Weber GR, et al. A novel ocular function for decorin in the aqueous humor outflow. Matrix Biol. 2021;97:1-19. - PubMed
  162. Keller KE, Bradley JM, Acott TS. Differential effects of ADAMTS-1, −4, and −5 in the trabecular meshwork. Invest Ophthalmol Vis Sci. 2009;50:5769-5777. - PubMed
  163. Gopal S. Syndecans in inflammation at a glance. Front Immunol. 2020;11:227. - PubMed
  164. Xian X, Gopal S, Couchman JR. Syndecans as receptors and organizers of the extracellular matrix. Cell Tissue Res. 2010;339:31-46. - PubMed
  165. Filla MS, Woods A, Kaufman PL, Peters DM. β1 And β3 integrins cooperate to induce syndecan-4-containing cross-linked actin networks in human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2006;47:1956-1967. - PubMed
  166. Filla MS, Clark R, Peters DM. A syndecan-4 binding peptide derived from laminin 5 uses a novel PKCepsilon pathway to induce cross-linked actin network (CLAN) formation in human trabecular meshwork (HTM) cells. Exp Cell Res. 2014;327:171-182. - PubMed
  167. Zhang W, Ge Y, Cheng Q, Zhang Q, Fang L, Zheng J. Decorin is a pivotal effector in the extracellular matrix and tumour microenvironment. Oncotarget. 2018;9:5480-5491. - PubMed
  168. Merle B, Malaval L, Lawler J, Delmas P, Clezardin P. Decorin inhibits cell attachment to thrombospondin-1 by binding to a KKTR-dependent cell adhesive site present within the N-terminal domain of thrombospondin-1. J Cell Biochem. 1997;67:75-83. - PubMed
  169. Schwartz MA, Ginsberg MH. Networks and crosstalk: integrin signalling spreads. Nat Cell Biol. 2002;4:E65-E68. - PubMed
  170. Yamada KM, Even-Ram S. Integrin regulation of growth factor receptors. Nat Cell Biol. 2002;4:E75-E76. - PubMed
  171. Legate KR, Wickstrom SA, Fassler R. Genetic and cell biological analysis of integrin outside-in signaling. Genes Dev. 2009;23:397-418. - PubMed
  172. Sieg DJ, Hauck CR, Ilic D, et al. FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol. 2000;2:249-256. - PubMed
  173. Moro L, Venturino M, Bozzo C, et al. Integrins induce activation of EGF receptor: role in MAP kinase induction and adhesion-dependent cell survival. EMBO J. 1998;17:6622-6632. - PubMed
  174. Merlo GR, Basolo F, Fiore L, Duboc L, Hynes NE. p53-dependent and p53-independent activation of apoptosis in mammary epithelial cells reveals a survival function of EGF and insulin. J Cell Biol. 1995;128:1185-1196. - PubMed
  175. Edwards G, Streuli C. Signalling in extracellular-matrix-mediated control of epithelial cell phenotype. Biochem Soc Trans. 1995;23:464-468. - PubMed
  176. Hennig R, Kuespert S, Haunberger A, Goepferich A, Fuchshofer R. Cyclic RGD peptides target human trabecular meshwork cells while ameliorating connective tissue growth factor-induced fibrosis. J Drug Target. 2016;24:952-959. - PubMed
  177. Brown EJ, Frazier WA. Integrin-associated protein (CD47) and its ligands. Trends Cell Biol. 2001;11:130-135. - PubMed
  178. Hoare MJ, Grierson I, Brotchie D, Pollock N, Cracknell K, Clark AF. Cross-linked actin networks (CLANs) in the trabecular meshwork of the normal and glaucomatous human eye in situ. Invest Ophthalmol Vis Sci. 2009;50:1255-1263. - PubMed
  179. Filla MS, Schwinn MK, Sheibani N, Kaufman PL, Peters DM. Regulation of cross-linked actin network (CLAN) formation in human trabecular meshwork (HTM) cells by convergence of distinct beta1 and beta3 integrin pathways. Invest Ophthalmol Vis Sci. 2009;50:5723-5731. - PubMed
  180. Filla MS, Meyer KK, Faralli JA, Peters DM. Overexpression and activation of αvβ3 integrin differentially affects TGFβ2 signaling in human trabecular meshwork cells. Cell. 2021;10:1923. - PubMed
  181. Filla MS, Faralli JA, Desikan H, Peotter JL, Wannow AC, Peters DM. Activation of αvβ3 integrin alters fibronectin fibril formation in human trabecular meshwork cells in a ROCK-independent manner. Invest Ophthalmol Vis Sci. 2019;60:3897-3913. - PubMed
  182. Acott TS, Kingsley PD, Samples JR, Van Buskirk EM. Human trabecular meshwork organ culture: morphology and glycosaminoglycan synthesis. Invest Ophthalmol Vis Sci. 1988;29:90-100. - PubMed
  183. Gabelt BT, Kaufman PL. Changes in aqueous humor dynamics with age and glaucoma. Prog Retin Eye Res. 2005;24:612-637. - PubMed
  184. Lutjen-Drecoll E, Schenholm M, Tamm E, Tengblad A. Visualization of hyaluronic acid in the anterior segment of rabbit and monkey eyes. Exp Eye Res. 1990;51:55-63. - PubMed
  185. Knepper PA, Goossens W, Palmberg PF. Glycosaminoglycan stratification of the juxtacanalicular tissue in normal and primary open-angle glaucoma. Invest Ophthalmol Vis Sci. 1996;37:2414-2425. - PubMed
  186. Cavallotti C, Feher J, Pescosolido N, Sagnelli P. Glycosaminoglycans in human trabecular meshwork: age-related changes. Ophthalmic Res. 2004;36:211-217. - PubMed
  187. Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol. 2003;4:33-45. - PubMed
  188. Isacke CM, Yarwood H. The hyaluronan receptor, CD44. Int J Biochem Cell Biol. 2002;34:718-721. - PubMed
  189. Kultti A, Rilla K, Tiihonen R, Spicer AP, Tammi RH, Tammi MI. Hyaluronan synthesis induces microvillus-like cell surface protrusions. J Biol Chem. 2006;281:15821-15828. - PubMed
  190. Kultti A, Pasonen-Seppanen S, Jauhiainen M, et al. 4-Methylumbelliferone inhibits hyaluronan synthesis by depletion of cellular UDP-glucuronic acid and downregulation of hyaluronan synthase 2 and 3. Exp Cell Res. 2009;315:1914-1923. - PubMed
  191. Rilla K, Pasonen-Seppanen S, Rieppo J, Tammi M, Tammi R. The hyaluronan synthesis inhibitor 4-methylumbelliferone prevents keratinocyte activation and epidermal hyperproliferation induced by epidermal growth factor. J Invest Dermatol. 2004;123:708-714. - PubMed
  192. Twarock S, Tammi MI, Savani RC, Fischer JW. Hyaluronan stabilizes focal adhesions, filopodia, and the proliferative phenotype in esophageal squamous carcinoma cells. J Biol Chem. 2010;285:23276-23284. - PubMed
  193. Cichy J, Pure E. The liberation of CD44. J Cell Biol. 2003;161:839-843. - PubMed
  194. Mokbel TH, Ghanem AA, Kishk H, Arafa LF, El-Baiomy AA. Erythropoietin and soluble CD44 levels in patients with primary open-angle glaucoma. Clin Experiment Ophthalmol. 2010;38:560-565. - PubMed
  195. Budak YU, Akdogan M, Huysal K. Aqueous humor level of sCD44 in patients with degenerative myopia and primary open-angle glaucoma. BMC Res Notes. 2009;2:224. - PubMed
  196. Nolan MJ, Giovingo MC, Miller AM, et al. Aqueous humor sCD44 concentration and visual field loss in primary open-angle glaucoma. J Glaucoma. 2007;16:419-429. - PubMed
  197. Knepper PA, Miller AM, Choi J, et al. Hypophosphorylation of aqueous humor sCD44 and primary open-angle glaucoma. Invest Ophthalmol Vis Sci. 2005;46:2829-2837. - PubMed
  198. Giovingo M, Nolan M, McCarty R, et al. sCD44 overexpression increases intraocular pressure and aqueous outflow resistance. Mol Vis. 2013;19:2151-2164. - PubMed
  199. Culty M, Nguyen HA, Underhill CB. The hyaluronan receptor (CD44) participates in the uptake and degradation of hyaluronan. J Cell Biol. 1992;116:1055-1062. - PubMed
  200. Hua Q, Knudson CB, Knudson W. Internalization of hyaluronan by chondrocytes occurs via receptor-mediated endocytosis. J Cell Sci. 1993;106:365-375. - PubMed
  201. Knudson W, Chow G, Knudson CB. CD44-mediated uptake and degradation of hyaluronan. Matrix Biol. 2002;21:15-23. - PubMed
  202. Tammi MI, Day AJ, Turley EA. Hyaluronan and homeostasis: a balancing act. J Biol Chem. 2002;277:4581-4584. - PubMed
  203. Dillinger AE, Guter M, Froemel F, et al. Intracameral delivery of layer-by-layer coated siRNA nanoparticles for glaucoma therapy. Small. 2018;14:e1803239. - PubMed
  204. de Kater AW, Melamed S, Epstein DL. Patterns of aqueous humor outflow in glaucomatous and nonglaucomatous human eyes. A tracer study using cationized ferritin. Arch Ophthalmol. 1989;107:572-576. - PubMed
  205. Last JA, Pan T, Ding Y, et al. Elastic modulus determination of normal and glaucomatous human trabecular meshwork. Invest Ophthalmol Vis Sci. 2011;52:2147-2152. - PubMed
  206. Raghunathan VK, Morgan JT, Park SA, et al. Dexamethasone stiffens trabecular meshwork, trabecular meshwork cells, and matrix. Invest Ophthalmol Vis Sci. 2015;56:4447-4459. - PubMed
  207. Wang K, Read AT, Sulchek T, Ethier CR. Trabecular meshwork stiffness in glaucoma. Exp Eye Res. 2017;158:3-12. - PubMed
  208. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia. 2001;44:129-146. - PubMed
  209. Bailey AJ, Paul RG, Knott L. Mechanisms of maturation and ageing of collagen. Mech Ageing Dev. 1998;106:1-56. - PubMed
  210. Tovar-Vidales T, Roque R, Clark AF, Wordinger RJ. Tissue transglutaminase expression and activity in normal and glaucomatous human trabecular meshwork cells and tissues. Invest Ophthalmol Vis Sci. 2008;49:622-628. - PubMed
  211. Deol M, Taylor DA, Radcliffe NM. Corneal hysteresis and its relevance to glaucoma. Curr Opin Ophthalmol. 2015;26:96-102. - PubMed
  212. Belovay GW, Goldberg I. The thick and thin of the central corneal thickness in glaucoma. Eye (Lond). 2018;32:915-923. - PubMed
  213. Yemanyi F, Vranka J, Raghunathan VK. Crosslinked extracellular matrix stiffens human trabecular meshwork cells via dysregulating beta-catenin and YAP/TAZ signaling pathways. Invest Ophthalmol Vis Sci. 2020;61:41. - PubMed
  214. Kim JH, Asthagiri AR. Matrix stiffening sensitizes epithelial cells to EGF and enables the loss of contact inhibition of proliferation. J Cell Sci. 2011;124:1280-1287. - PubMed
  215. Morgan JT, Raghunathan VK, Chang YR, Murphy CJ, Russell P. The intrinsic stiffness of human trabecular meshwork cells increases with senescence. Oncotarget. 2015;6:15362-15374. - PubMed
  216. Allen JL, Cooke ME, Alliston T. ECM stiffness primes the TGFbeta pathway to promote chondrocyte differentiation. Mol Biol Cell. 2012;23:3731-3742. - PubMed
  217. Schlunck G, Han H, Wecker T, Kampik D, Meyer-ter-Vehn T, Grehn F. Substrate rigidity modulates cell matrix interactions and protein expression in human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2008;49:262-269. - PubMed
  218. Thomasy SM, Wood JA, Kass PH, Murphy CJ, Russell P. Substratum stiffness and latrunculin B regulate matrix gene and protein expression in human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2012;53:952-958. - PubMed
  219. Wight TN. Versican: a versatile extracellular matrix proteoglycan in cell biology. Curr Opin Cell Biol. 2002;14:617-623. - PubMed
  220. Smith ML, Gourdon D, Little WC, et al. Force-induced unfolding of fibronectin in the extracellular matrix of living cells. PLoS Biol. 2007;5:e268. - PubMed
  221. Abu-Lail NI, Ohashi T, Clark RL, Erickson HP, Zauscher S. Understanding the elasticity of fibronectin fibrils: unfolding strengths of FN-III and GFP domains measured by single molecule force spectroscopy. Matrix Biol. 2006;25:175-184. - PubMed
  222. Zhong C, Chrzanowska-Wodnicka M, Brown J, Shaub A, Belkin AM, Burridge K. Rho-mediated contractility exposes a cryptic site in fibronectin and induces fibronectin matrix assembly. J Cell Biol. 1998;141:539-551. - PubMed
  223. Antia M, Baneyx G, Kubow KE, Vogel V. Fibronectin in aging extracellular matrix fibrils is progressively unfolded by cells and elicits an enhanced rigidity response. Faraday Discuss. 2008;139:229-249. discussion 309-25, 419-20. - PubMed
  224. Baneyx G, Baugh L, Vogel V. Coexisting conformations of fibronectin in cell culture imaged using fluorescence resonance energy transfer. Proc Natl Acad Sci U S A. 2001;98:14464-14468. - PubMed
  225. Grant RP, Spitzfaden C, Altroff H, Campbell ID, Mardon HJ. Structural requirements for biological activity of the ninth and tenth FIII domains of human fibronectin. J Biol Chem. 1997;272:6159-6166. - PubMed
  226. Krammer A, Craig D, Thomas WE, Schulten K, Vogel V. A structural model for force regulated integrin binding to fibronectin's RGD-synergy site. Matrix Biol. 2002;21:139-147. - PubMed
  227. Cao L, Nicosia J, Larouche J, et al. Detection of an integrin-binding mechanoswitch within fibronectin during tissue formation and fibrosis. ACS Nano. 2017;11:7110-7117. - PubMed
  228. Jones FS, Jones PL. The tenascin family of ECM glycoproteins: structure, function, and regulation during embryonic development and tissue remodeling. Dev Dyn. 2000;218:235-259. - PubMed
  229. Jalkanen S, Jalkanen M. Lymphocyte CD44 binds the COOH-terminal heparin-binding domain of fibronectin. J Cell Biol. 1992;116:817-825. - PubMed
  230. Wu YJ, La Pierre DP, Wu J, Yee AJ, Yang BB. The interaction of versican with its binding partners. Cell Res. 2005;15:483-494. - PubMed
  231. Filla MS, Liu X, Nguyen TD, et al. In vitro localization of TIGR/MYOC in trabecular meshwork extracellular matrix and binding to fibronectin. Invest Ophthalmol Vis Sci. 2002;43:151-161. - PubMed
  232. Zollinger AJ, Smith ML. Fibronectin, the extracellular glue. Matrix Biol. 2017;60-61:27-37. - PubMed
  233. Chen Y, Zardi L, Peters DM. High-resolution cryo-scanning electron microscopy study of the macromolecular structure of fibronectin fibrils. Scanning. 1997;19:349-355. - PubMed
  234. Mitsi M, Hong Z, Costello CE, Nugent MA. Heparin-mediated conformational changes in fibronectin expose vascular endothelial growth factor binding sites. Biochemistry. 2006;45:10319-10328. - PubMed
  235. Inatani M, Tanihara H, Katsuta H, Honjo M, Kido N, Honda Y. Transforming growth factor-beta 2 levels in aqueous humor of glaucomatous eyes. Graefes Arch Clin Exp Ophthalmol. 2001;239:109-113. - PubMed
  236. Robertson JV, Golesic E, Gauldie J, West-Mays JA. Ocular gene transfer of active TGF-beta induces changes in anterior segment morphology and elevated IOP in rats. Invest Ophthalmol Vis Sci. 2010;51:308-318. - PubMed
  237. Shepard AR, Millar JC, Pang IH, Jacobson N, Wang WH, Clark AF. Adenoviral gene transfer of active human transforming growth factor-β2 elevates intraocular pressure and reduces outflow facility in rodent eyes. Invest Ophthalmol Vis Sci. 2010;51:2067-2076. - PubMed
  238. Fleenor DL, Shepard AR, Hellberg PE, Jacobson N, Pang IH, Clark AF. TGFβ2-induced changes in human trabecular meshwork: implications for intraocular pressure. Invest Ophthalmol Vis Sci. 2006;47:226-234. - PubMed
  239. Schlotzer-Schrehardt U, Zenkel M, Kuchle M, Sakai LY, Naumann GO. Role of transforming growth factor-beta1 and its latent form binding protein in pseudoexfoliation syndrome. Exp Eye Res. 2001;73:765-780. - PubMed
  240. Junglas B, Kuespert S, Seleem AA, et al. Connective tissue growth factor causes glaucoma by modifying the actin cytoskeleton of the trabecular meshwork. Am J Pathol. 2012;180:2386-2403. - PubMed

Publication Types

Grant support